Profusa Clears MDR Quality Hurdle, But Stark Financial Realities Loom

BERKELEY, CA – September 24, 2026 — In the high-stakes arena of medical technology, the distance between clinical brilliance and commercial viability is often measured in regulatory checkpoints and cash runways. Today, Profusa, Inc. announced a critical step forward in the former, even as it battles fiercely to secure the latter.

The Berkeley-based digital health company, which is pioneering tissue-integrated biosensors, confirmed it has received a positive decision from the French notified body GMED regarding the certification of its quality management system to ISO 13485. Expected to be formally issued in early October, this certification is an essential prerequisite for securing a CE mark under the European Union’s notoriously stringent Medical Device Regulation (MDR).

For professionals tracking the post-MDD regulatory environment in Europe, this is no small feat. Yet, a closer examination of Profusa’s trajectory reveals a company attempting to thread a remarkably tight needle: advancing a revolutionary clinical platform while navigating acute balance sheet distress and executing a radically dilutive corporate pivot.

Navigating the EU MDR Labyrinth

The transition to the EU MDR framework has created a severe bottleneck for medical device manufacturers worldwide. By securing a positive ISO 13485 audit from GMED—one of the few notified bodies with deep domain competence in bio-integrated sensory implants—Profusa has cleared a major administrative hurdle.

"We are pleased with the progress we have made in strengthening our quality management system, responding to GMED’s requirements and, importantly, receiving a positive decision regarding ISO 13485 certification," said Ben Hwang, Ph.D., President of Profusa, in the company's press release. "This represents a significant milestone for Profusa and reflects the outstanding work our team has undertaken to address GMED’s observations and advance our path toward completion of MDR conformity assessment for the Lumee Oxygen Platform."

However, regulatory experts caution that quality management certification is merely the first phase. The company must now subject its Lumee Oxygen Platform to Phase 2 of the MDR conformity assessment, which involves rigorous scrutiny of device technical documentation, biocompatibility, and clinical evaluation. Across the European MedTech landscape, queue times for implantable Class IIb and Class III technical documentation reviews currently stretch an additional nine to eighteen months following an initial quality audit.

The Promise of Injectable Biosensors

If Profusa can survive the regulatory gauntlet, the clinical upside is substantial. The Lumee Oxygen Platform represents a paradigm shift in how clinicians monitor tissue perfusion, particularly in patients suffering from chronic limb-threatening ischemia (CLTI) and severe wound complications.

Traditional tissue perfusion monitoring, such as Transcutaneous Oximetry (TcPO2), relies on heated surface electrodes that are notoriously operator-dependent, require lengthy equilibration times, and cannot be used dynamically during surgical interventions. Profusa’s alternative is an elegant feat of bioengineering: a five-millimeter porous hydrogel scaffold embedded with an oxygen-sensitive metalloporphyrin dye. Injected subcutaneously, the sensor integrates directly with local capillaries without triggering a foreign-body encapsulation response. An external optical reader patch then excites the dye, measuring the phosphorescence decay to provide continuous, real-time interstitial oxygen data directly to a mobile app.

The clinical validation is already turning heads in the vascular surgery community. In the landmark "Si Se Puede" trial published in the Journal of Vascular Surgery, and the subsequent European OMNIA multicenter study, the biosensors provided dynamic, intra-operative microvascular perfusion data that standard angiograms simply could not detect. For patients at risk of amputation, this real-time "GPS" for tissue oxygenation could mean the difference between localized healing and catastrophic tissue loss. Furthermore, an ongoing trial at the University of California, San Francisco is actively comparing the Lumee platform against standard Transcutaneous Oxygen Pressure under induced hemodynamic stress, a critical step for establishing the clinical equivalence required by both European and US regulators.

A Race Against the Balance Sheet

Despite the technological elegance of the Lumee platform, Profusa’s financial reality is stark. Following a reverse merger with a special purpose acquisition company in July 2025, the newly public entity has struggled to maintain its footing on the Nasdaq Capital Market.

An analysis of recent Securities and Exchange Commission filings paints a picture of a company in severe distress. At the close of the second quarter of 2026, Profusa reported a stockholders’ equity deficit of roughly $27.1 million and just $719,000 in cash and cash equivalents. With a quarterly operating cash burn exceeding $2.6 million, the standalone entity's cash runway without external financing was perilously short.

These pressures culminated in a 1-for-4 reverse stock split in August to regain compliance with Nasdaq’s minimum bid price rule. While a Nasdaq Hearings Panel recently determined the company had regained compliance, Profusa remains under a strict one-year regulatory monitor, leaving zero margin for error in the public markets.

The G3 Vision Labs Hail Mary

To solve its structural deficit and establish cash-generating operations, Profusa has initiated a massive corporate pivot. In late July, the company signed a call option agreement to acquire G3 Vision Labs, Inc., a profitable diagnostics conglomerate specializing in clinical drug monitoring and toxicology, boasting an estimated $111 million in 2025 net revenues.

This acquisition is essentially a lifeline, but it comes with heavy contingencies and staggering dilution for legacy shareholders. To exercise the option, Profusa must close at least $30 million in third-party financings. Furthermore, the transaction structure relies heavily on Series A Non-Voting Convertible Preferred shares. Upon shareholder approval, the conversion of these preferred shares will result in the issuance of over 100 million equivalent common shares—a tidal wave of dilution for a company that had fewer than a million post-split common shares outstanding prior to the deal.

If successful, the combined entity will operate as a diversified public diagnostics company, utilizing G3's cash flow to fund the commercialization of the Lumee platform. Even then, market access challenges await in Europe. Profusa will need to navigate fragmented reimbursement landscapes, such as securing an NUB innovation code in Germany or LPPR listing in France, while lobbying to integrate injectable biosensors into the primary clinical guidelines of the European Society for Vascular Surgery and the Global Vascular Guidelines on CLTI. Without inclusion in these professional society guidelines, driving high-volume clinician adoption will remain an uphill battle.

Profusa’s journey is emblematic of the modern MedTech paradox. The company possesses a genuinely transformative technology that could redefine peripheral vascular care, yet its survival depends entirely on executing complex financial engineering in a brutal macroeconomic climate. The ISO 13485 certification is a vital victory, but the true test of Profusa's resilience will unfold in the capital markets over the coming months.